Skip to main content
Premium Trial:

Request an Annual Quote

The Heady Days of RNAi

Well, knock GTO over with a feather: we never thought we'd see the day that "RNA interference" made it into a Wall Street Journal headline. This article reports on recent results from Alnylam Pharmaceuticals' human trial for its RNAi-based drug for respiratory syncytial virus. The story quotes Alnylam CEO John Maraganore as saying, "This is really the first moonwalk for RNAi therapeutics." Michael Jackson would be so proud.

 

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.